UK-based biopharmaceutical giant AstraZeneca has unveiled its newly expanded manufacturing facility in Coppell, Texas, US.
Initially announced in November 2024, the enhanced site represents an investment of $445m. It is part of AstraZeneca’s $50bn investment strategy in the US in medicines manufacturing and R&D.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AstraZeneca’s Coppell facility is the sole global manufacturing facility of Lokelma, a prescription medication for treating hyperkalemia. The expansion will reportedly double the drug’s production.
The company has added a new 836sqm building with two new novel manufacturing lines as part of the expansion. It will provide drug substance and drug product laboratory testing. Additionally, it will also offer warehousing, manufacturing utilities, and administrative space.
Jim Fox, senior vice president of Americas Supply Operations at AstraZeneca, called the Coppell facility a critical pillar in global healthcare.
“It has played an important role in supporting the local workforce over the past 10 years. The expansion underscores our commitment to patients and support for Texas’ long-term vision for scientific growth and innovation,” he added.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. Last week, it announced a massive $4.5bn manufacturing facility in Albemarle County, Virginia. Furthermore, since 2024, it has announced investments in Rockville and Gaithersburg (Maryland), Massachusetts, California, and Indiana.
